EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms

Ramya Mahadevan iD, Estefany Garcia, Rajnikant Sharma, Hongqiang Qiu iD, Ahmed Elsheikh, Robert Parambi, Cely Saad Abboud, Fernando Pasteran, Maria Soledad Ramirez iD, Keith S Kaye, Robert A Bonomo iD, Gauri G Rao iD

Antimicrobial Agents and Chemotherapy · 04.02.2026 · 70 (2)

DOI: 10.1128/aac.00782-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.02.2026. Verfasst von Ramya Mahadevan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, L…. Hauptthemen laut MEDLINE: Polymyxin B, Klebsiella pneumoniae, Anti-Bacterial Agents, Carbapenems. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increased resistance to β-lactams/β-lactamase inhibitors by mutations in β-lactamase genes, porins, and efflux pumps complicates the management of carbapenem-resistant Klebsiella pneumoniae (CRKP). Polymyxin B (PMB)-based combination therapy is the best alternative treatment for middle and low-income countries that cannot access the latest medicines. It is crucial to know both phenotypic and genotypic characteristics of a pathogen to understand the killing effect of each drug and its combinations. Hence, our objective was to incorporate mechanistic insights gained from resistance mechanisms of each isolate to develop a mechanism-based pharmacokinetic/pharmacodynamic model. Six clinical CRKP isolates with diverse genotypic resistance expressing bla KPC , bla NDM , porin, and mgrB mutations were used for static concentration time kill (SCTK) assays to evaluate the rate and extent of killing by monotherapy, double and triple combinations using PMB (0.5–64 mg/L), meropenem (10–120 mg/L), and fosfomycin (75–500 mg/L). Isolate BRKP28 expressed non-functional MgrB (a regulatory protein) and high-level phenotypic resistance (PMB MIC: >128 mg/L). In line with the observed resistance, the model estimated that BRKP28 had a reduced maximum killing rate constant for PMB (3.61 h⁻¹) relative to other isolates. The mechanistic synergy of PMB, due to outer membrane disruption, was incorporated into three isolates with porin mutations. PMB demonstrated 83%–88% mechanistic synergy with meropenem and 81%–98% with fosfomycin. The model further estimated that a very low concentration of PMB (0.49–0.64 mg/L) was sufficient to achieve 50% of the maximum synergy. Simulations using population pharmacokinetic models showed that combination therapy of PMB (1 mg/kg q12h) and fosfomycin (8 g q8h) achieved >73% reduction in area under the bacterial load-versus-time curve across four isolates. The triple combination therapy achieved a 67.7% reduction in non-carbapenamase producing isolate. These findings demonstrates that a low PMB dosing regimen (1 mg/kg q12h) can produce synergistic effects in combination therapy and may be effective in managing infections caused by CRKP, including PMB resistant isolates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyxin BKlebsiella pneumoniaeAnti-Bacterial AgentsCarbapenemsCarbapenem-Resistant EnterobacteriaceaeMicrobial Sensitivity TestsDrug Therapy, CombinationPorinsHumansbeta-LactamasesKlebsiella InfectionsBacterial ProteinsGenotypeMeropenemMutationPhenotypeDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

carbapenem resistant Klebsiella pneumoniaemechanism based PK/PD modelpolymyxin B based combination therapy

Substanzen

Polymyxin BAnti-Bacterial AgentsCarbapenemsPorinsbeta-LactamasesBacterial ProteinsMeropenem

Autor:innen und Institutionen

  • Titus Family Department of Clinical Practice, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
  • Division of Pharmaceutics and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • College of Pharmacy, Fujian Medical University, Fuzhou, People's Republic of China.
  • Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
  • Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, Antimicrobial Service of the National Institute of Infectious Diseases (ANLIS Dr. Carlos G. Malbrán), Buenos Aires, Argentina.

ORCID-Profile: Ramya Mahadevan, Hongqiang Qiu, Maria Soledad Ramirez, Robert A Bonomo, Gauri G Rao

Zitieren

APA

Mahadevan, R., Garcia, E., Sharma, R., Qiu, H., Elsheikh, A., Parambi, R., Abboud, C. S., Pasteran, F., Ramirez, M. S., Kaye, K. S., Bonomo, R. A., & Rao, G. G. (2026). A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms. Antimicrobial Agents and Chemotherapy, 70(2). https://doi.org/10.1128/aac.00782-25

Vancouver

Mahadevan R, Garcia E, Sharma R, Qiu H, Elsheikh A, Parambi R, et al. A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms. Antimicrobial Agents and Chemotherapy. 2026;70(2). doi:10.1128/aac.00782-25

BibTeX
@article{Mahadevan2026,
  author = {Mahadevan, Ramya and Garcia, Estefany and Sharma, Rajnikant and Qiu, Hongqiang and Elsheikh, Ahmed and Parambi, Robert and Abboud, Cely Saad and Pasteran, Fernando and Ramirez, Maria Soledad and Kaye, Keith S and Bonomo, Robert A and Rao, Gauri G},
  title = {A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {2},
  doi = {10.1128/aac.00782-25}
}
Kostenlos starten →